Amylyx Pharmaceuticals launches Phase 3 LUCIDITY trial with first participant dose

loss of consciousness, and seizures. These events can result in an array of challenges, such as difficulty driving, working, living independently, or participating in social activities. The unpredictable nature of hypoglycemic episodes can severely impact the day-to-day lives of individuals struggling with PBH, highlighting the urgent need for effective treatment options.

Amylyx Pharmaceuticals, Inc. has embarked on a significant milestone with the commencement of the pivotal Phase 3 LUCIDITY clinical trial involving avexitide, a groundbreaking GLP-1 receptor antagonist, specifically tailored to address the complexities of post-bariatric hypoglycemia. Led by innovative medical personnel, the trial is a crucial step toward providing relief to those grappling with PBH and its debilitating consequences. Dr. Camille L. Bedrosian, the Chief Medical Officer at Amylyx, expressed enthusiasm regarding the initiation of the Phase 3 trial, underscoring the promising potential of avexitide to alleviate the burden of repeated hypoglycemic incidents commonly experienced by individuals post-bariatric surgery.

The LUCIDITY trial is envisioned to revolutionize the landscape of PBH treatment by focusing on the reduction of hypoglycemic events as the primary goal, supported by the remarkable outcomes observed in five prior clinical trials of avexitide. These trials have consistently demonstrated dose-dependent benefits associated with avexitide, showcasing substantial reductions in hypoglycemic occurrences. Furthermore, safety and tolerability assessments have reinforced the favorable profile exhibited by avexitide across multiple clinical investigations.

Dr. Marilyn Tan, a notable Principal Investigator and Clinical Associate Professor of Medicine at Stanford University School of Medicine, highlighted the profound impact of PBH on affected individuals, emphasizing the critical need for therapeutic interventions to combat the condition’s far-reaching implications. The formidable symptoms caused by recurrent hypoglycemic events, such as cognitive impairment, unconsciousness, and seizures, precipitate challenges in independent living, underscoring the urgency of finding effective solutions like avexitide.

A vital feature of the LUCIDITY trial is its rigorous design, characterized by a multicenter, randomized, double-blind, placebo-controlled structure, which aims to ascertain the efficacy and safety of avexitide across a diverse cohort of participants. The study will assess the reduction in Level 2 and Level 3 hypoglycemic events as the FDA-agreed primary endpoint, covering a 16-week treatment period following a comprehensive screening phase. Moreover, participants completing the trial will have the opportunity to engage in an extended open-label extension period to further evaluate the long-term benefits of avexitide.

Amylyx is fully committed to advancing the LUCIDITY trial and expects to complete recruitment by 2025, with initial findings anticipated in the first half of 2026. This continued dedication stems from the company’s financial sustainability through 2026, ensuring the successful execution of pivotal trials. Avexitide’s breakthrough potential in addressing PBH signifies a significant leap forward in providing relief to individuals affected by this challenging condition, offering hope for a brighter, healthier future.